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Abstract
Background: Eczema is a common chronic or chronically relapsing, inflammatory skin disease that exerts a
substantial negative impact on quality of life (QoL). The Harmonising Outcome Measures for Eczema (HOME)
initiative has used a consensus-based process which identified QoL as one of the four core outcome domains to be
assessed in all eczema clinical trials. A number of measurement instruments exist to measure QoL in infants, children,
and adolescents with eczema, and there is a great variability in both content and quality of the instruments used.
Therefore, the objective of the proposed research is to comprehensively and systematically assess the measurement
properties of the existing measurement instruments that were developed and/or validated for the measurement of
patient-reported QoL in infants, children, and adolescents with eczema.
Methods/design: This study is a systematic review of the measurement properties of patient-reported measures of
QoL developed and/or validated for infants, children, and adolescents with eczema. A systematic literature search will
be carried out in MEDLINE via PubMed and EMBASE using a selection of relevant search terms. Eligible studies will be
primary empirical studies evaluating, describing, or comparing measurement properties of QoL instruments for infants,
children, and adolescents with eczema. Two reviewers will independently perform eligibility assessment and data
abstraction. Evidence tables will be used to record study characteristics, instrument characteristics, measurement
properties, and interpretability. The adequacy of the measurement properties will be assessed using predefined criteria.
The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist will be used
to evaluate the methodological quality of included studies. A best evidence synthesis will be undertaken if more than
one study has examined a particular measurement property.
Discussion: The proposed systematic review will yield a comprehensive assessment of measurement properties of
existing QoL instruments in infants, children, and adolescents with eczema. The results will serve as a basis to
recommend a QoL measurement instrument for infants, one for children, and one for adolescents for use in future
clinical trials.
Systematic review registration: PROSPERO CRD42015023483
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Background
Eczema (synonymous with atopic eczema, atopic derma-
titis) represents the most common chronic disease in chil-
dren in many countries [1]. Its main symptom is persistent
pruritus [2]. The disease has a negative impact on the qual-
ity of life (QoL) of the patients and their families [3, 4].
Despite the fact that various interventions exist for eczema,
uncertainties concerning the best treatment options re-
main. A major reason for this situation is the inconsistent
use of varying eczema outcome measures in randomized
controlled trials, making the comparison of interventions
across these trials in systematic reviews and meta-analyses
difficult. Thus, outcome measures in clinical trials of
(pediatric) eczema patients need to be improved [5].
An internationally acknowledged way to ameliorate
this unsatisfying situation is the development of a core
outcome set (COS) [6]. The Harmonising Outcome
Measures for Eczema (HOME) initiative [7] aims to de-
velop a COS for eczema. Clinical signs measured by
means of a physician-assessed instrument, symptoms,
long-term control of eczema flares, and QoL were
agreed on as the core outcome domains to be assessed
in all future eczema trials [8, 9]. There was broad inter-
national consensus among clinicians, patients, and
methodologists that the Outcome Measures in Rheuma-
tology (OMERACT) quality criteria “truth, discrimin-
ation, and feasibility” [10] need to be met for eczema
outcome measures to be recommended by the HOME
initiative [9]. The next crucial step in the process of
standardizing eczema outcome measurements is now
the identification of appropriate instruments to measure
each of the four core outcome domains of atopic eczema
[11]. For adult QoL measurement instruments, this has
already been undertaken, using methods similar to this
proposed review [12]. The results have been published
[13]. As the methodology of this systematic review will
be in large parts identical to the one applied in the re-
view on adult QoL instruments, content and wording of
this protocol are very similar to the published protocol
of the review on adult QoL instruments [12]. This pertains
specifically to the methods section. To ensure transpar-
ency, differences in the methodology of both reviews are
highlighted in the “Differences between this review and
previously suggested methodology” section.
Objectives
1. To systematically assess the measurement properties
of patient- or parent-reported measurement instru-
ments of QoL for infants, children, and adolescents
with eczema
2. To identify outcome measurement instruments for
QoL in infants, children, and adolescents with
eczema
a. That meet the predefined criteria to be
recommended [10, 9] for the measurement of
QoL in future eczema trials
b. That have the potential to be recommended in
the future depending on the results of further
validation studies
c. That do not meet the predefined criteria to be
recommended [10, 9] and therefore should not be
used any more
3. To provide the evidence base for an international
consensus process
a. To further standardize the assessment of QoL in
infants, children, and adolescents with eczema in
clinical trials
b. To prioritize further research concerning QoL




The methods for this systematic review have been devel-
oped according to the recommendations from the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocols (PRISMA-P) statement [14],
and a populated PRISMA-P checklist is available as an
Additional file 1 to this protocol. This protocol has been
registered in the International Prospective Register of
Systematic Reviews (PROSPERO): CRD42015023483.
Literature search
A systematic literature search will be performed in
PubMed and EMBASE. The search strategy will contain
blocks of search terms related to the following aspects:
1. Construct of interest: quality of life
2. Target population: (atopic) eczema (Table 1)
3. Measurement properties: the precise PubMed search
filter for finding studies on measurement properties
developed by Terwee et al. will be used to identify
relevant articles [15]. This filter has a sensitivity of
93.1 % and a precision of 9.4 %
4. Interpretability
The search will not be restricted with respect to the
publication time of retrieved studies. The entire search
strategy is available as an Additional file 2 to this protocol.
The systematic electronic search will be supplemented by
hand searching of reference lists of studies included and
key articles on this topic. Furthermore, an additional
search will be performed in each database, including the
names of the instruments which are found in the initial
search. The PROQOLID (www.proqolid.org) database, an
online database of QoL instruments, will be searched. The
initial search in PubMed and EMBASE will be carried out
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on a single day that will be reported in the final review,
whereas the hand searching process will be performed
during the eligibility assessment of articles, which may
take several weeks. The additional search of each database
will be done, after the eligibility assessment has been com-
pleted, on a single day.
Eligible studies
A study will be included if it is published as a full-text
paper and concerns the development (“development
paper”) and/or evaluation of the measurement properties
(“validation paper”) of instruments that measure QoL or
health-related quality of life (HrQoL) in infants, children,
and adolescents with eczema. Measurement instruments
that assess both the QoL of children and caregivers will be
included if separate scores for the QoL of the child and
for the QoL of the caregiver can be calculated. Generic
QoL measurement instruments for infants, children, and
adolescents and measurement instruments assessing solely
the QoL of caregivers will not be considered eligible. The
HOME initiative decided in 2011 that generic QoL meas-
urement instruments are not eligible for the COS [16].
QoL measurement instruments for caregivers will be in-
vestigated in a separate review. To be eligible, at least
50 % of a study’s population must consist of eczema pa-
tients younger than 16 years of age. A study with a mixed
patient sample will be eligible either if it presents a sub-
group analysis for infants, children, and adolescents with
eczema or if infants, children, and adolescents with
eczema constitute at least 50 % of the study population.
The measurement instrument must be a self- or proxy-
reported questionnaire. Articles that report indirect
evidence, for instance, by using data obtained within
the context of a clinical trial, will not be considered
eligible. Articles assessing the measurement properties
of dermatology-specific instruments in non-eczema
samples will not be considered eligible.
Study selection
Two reviewers will independently judge titles and ab-
stracts retrieved in the literature search and, at a sec-
ond stage, full-text articles for eligibility (Table 1).
Disagreements will be resolved by consensus-seeking
discussions within the research team.
Data extraction
Relevant data from all included articles will be summa-
rized in evidence tables. The evidence tables drafted for
the adults’ review [12] will be slightly adapted. Data from
each article included will be extracted independently
by two reviewers. Reviewers will work in pairs on
defined sets of articles. Disagreements will be resolved
by consensus-seeking discussions within the research
team.
Evidence tables will include the following: reference,
geographical location, language, setting, study type, key
characteristics of study subjects, name of measurement
instruments, domains measured, number of items and
(sub)scales, number and type of response categories, re-
call period in the questions, scoring algorithm, time
needed for administration, mode of administration, tar-
get population for whom the questionnaire was origin-
ally developed, how a full copy of the questionnaire can
be obtained, the instructions given to those who
complete the questionnaire, the available versions and
translations of the questionnaire, results of the measure-
ment properties, all items from the COnsensus-based
Standards for the selection of health Measurement IN-
struments (COSMIN) box Generalisability, and all items
from the COSMIN box Interpretability [17, 18].
If general characteristics of an instrument (that is,
name of measurement instrument, number of items and
(sub)scales, number and type of response categories,
recall period in the questions, scoring algorithm, time
needed for administration, mode of administration,
target population for whom the questionnaire was
originally developed, how a full copy of the question-
naire can be obtained, the instructions given to those
who complete the questionnaire, the available versions
and translations of the questionnaire) cannot be
extracted from the studies included, the original
development paper may be consulted to obtain miss-
ing information.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Population Eczema (synonyms: atopic eczema, atopic dermatitis,
neurodermatitis); populations younger than 16 years of age
Populations with other skin diseases than eczema, populations of
adults with eczema, carers of infants/children with eczema
Study design Development study, validation study Linguistic validation studies
Outcome Quality of life, health-related quality of life Signs, disease severity measure, disease control measure,




Self- or proxy-reported measurement instrument All others
Publication type Articles with available full text Abstracts
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Content comparison
An overview of the content of each instrument on con-
tent domain level will be presented in order to visualize
the content covered by the different instruments. The
original development paper will be consulted to obtain
this information.
Assessment of the methodological quality of included
studies
The COSMIN checklist [17–19] will be used to evaluate
the methodological quality of included studies. In the
COSMIN checklist (www.cosmin.nl), four domains are
distinguished (reliability, validity, responsiveness, and in-
terpretability) with related measurement properties and
aspects of measurement properties. These are listed in
Table 2 (adapted from Mokkink LB et al. [18]).
For each measurement property, the COSMIN checklist
consists of 5 to 18 items covering methodological stan-
dards (organized in nine boxes for the nine measurement
properties). In addition, each item can be scored on a 4-
point rating scale (that is, “poor,” “fair,” “good,” “excellent”).
Taking the lowest rating for each item in one box, an over-
all quality score (“poor,” “fair,” “good,” “excellent”) is
obtained for each measurement property separately [20].
Assessment of measurement properties and further
characteristics of QoL instruments
We will assess all measurement properties from the
COSMIN checklist in this review, with the exception of
the measurement property “criterion validity,” which will
not be considered for the purpose of this systematic re-
view, since there is no gold standard for QoL. Data on
interpretability and feasibility will be collected where
presented. With the exception of content comparison
and instrument characteristics, we will regard different
language versions of the same questionnaire separately
throughout the review. Our principal reason for doing
so is the fact that it is problematic to assume that differ-
ent language versions of measurement instruments ex-
hibit the same measurement properties. Strictly
speaking, it is the measurements themselves that are
valid, reliable, and responsive and not the instruments
per se.
Assessment of the adequacy of the measurement
instruments
The predefined criteria for rating the adequacy of the
measurement instruments recommended by the COS-
MIN group will be used in a slightly modified version
[21] (Table 3). These criteria are in accordance with the
OMERACT filter [10], which has been adopted by the
HOME initiative [9] and applied in a previous review on
atopic eczema outcome measures [22]. The measure-
ment property “hypothesis testing” will be split into the
aspects convergent/divergent (defined as the correlation
between instruments measuring similar/different con-
structs [23]) and discriminative validity (defined as the
ability of a measurement instrument to distinguish be-
tween different subgroups of patients [23]) for this re-
view. An overall rating for hypothesis testing will be
obtained from both aspects in the end (see “Generating
recommendations for the use of QoL measurement in-
struments for eczema” section). Where studies apply
item response theory (IRT) methods in the evaluation of
measurement properties, rather than in the development
of measurement instruments, we will be able to assess
the adequacy and methodological quality of internal
consistency, construct validity, structural validity, and
cross-cultural validity.
Best evidence synthesis
If an instrument has been evaluated in multiple stud-
ies, findings will be synthesized if the characteristics
of the included studies are sufficiently similar, if the
results of the studies do not show significantly differ-
ent or conflicting findings, and if the methodological
quality of the included studies is sufficient [24]. The
criteria for best evidence synthesis are outlined in
Table 4.
Generating recommendations for the use of QoL
measurement instruments for eczema
For each instrument identified in the review, a standard-
ized recommendation for usage or required future valid-
ation work will be made depending on the
methodological quality of included studies and on the
adequacy of the instrument (Table 5). According to the
results of the HOME II meeting [9], all three criteria of
the OMERACT filter [10], that is, truth, discrimination,
and feasibility, have to be met by an outcome measure
to be recommended by the HOME initiative. Although
convergent/divergent and discriminative validity will be
regarded separately throughout the review, the findings
for these two aspects of hypothesis testing will be syn-
thesized according to the following criteria: in case of
conflicting ratings, the worse rating determines the over-
all rating for hypothesis testing; if one of the aspects ob-
tains an indeterminate rating, the rating for the other
aspect determines the overall rating for hypothesis
testing.
Four categories of recommendation will be made:
A. QoL measurement instrument meets all
requirements and is recommended for use.
B. QoL measure meets two or more adequacy items,
but performance in all other required adequacy
items is unclear, so that the outcome measure has
the potential to be recommended in the future
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Table 2 Definitions of domains, measurement properties, and aspects of measurement properties
Domain Measurement property Aspect of a measurement
property
Definition
Reliability The degree to which the measurement is free from measurement error.
Reliability (extended definition) The extent to which scores for patients who have not changed is the same for repeated measurement
under several conditions: for example, using different sets of items from the same HR-PROs (internal
consistency), over time (test-retest) by different persons on the same occasion (inter-rater) or by the
same persons (i.e., raters or responders)
on different occasions (intra-rater).
Internal consistency The degree of interrelatedness among the items.
Reliability The proportion of total variance in the measurements which is because of “true”a differences
among patients.
Measurement error The systematic and random error of a patient’s score that is not attributed to true change of the
construct to be measured.
Validity The degree to which an HR-PRO instrument measures the construct(s) it purports to measure.
Content validity The degree to which the content of an HR-PRO instrument is an adequate reflection of the construct
to be measured.
Face validity The degree to which (the items of) an HR-PRO instrument indeed looks as though they are an adequate
reflection of the construct to be measured.
Construct validity The degree to which the scores of an HR-PRO instrument are consistent with hypotheses (for instance
with regard to internal relationships, relationships to scores of other instruments, or differences between
relevant groups) based on the assumption that the HR-PRO instrument validly measures the construct
to be measured.
Structural validity The degree to which the scores of an HR-PRO instrument are an adequate reflection of the dimensionality
of the construct to be measured.
Hypothesis testing Idem construct validity.
Cross-cultural validity The degree to which the performance of the items on a translated or culturally adapted HR-PRO instrument
are an adequate reflection of the performance of the items of the original version of the HR-PRO instrument.
Responsiveness The ability of an HR-PRO instrument to detect change over time in the construct to be measured.
Responsiveness Idem responsiveness.
Interpretabilityb The degree to which one can assign qualitative meaning—that is, clinical or commonly understood
connotations—to an instrument’s quantitative scores or changes in scores.
HR-PROs health-related patient-reported outcomes, CTT classical test theory
aThe word “true” must be seen in the context of the CTT, which states that any observation is composed of two components—a true score and error associated with the observation. “True” is the average score that
would be obtained if the scale were given an infinite number of times. It refers only to the consistency of the score and not to its accuracy [26]












Table 3 Adequacy criteria for measurement properties adapted from [21] and [27]
Property Rating Adequacy criteria
Reliability
Internal consistency (CTT methods applied) + Cronbach’s alpha(s) ≥0.70
? Cronbach’s alpha not determined
− Cronbach’s alpha(s) <0.70
Internal consistency (IRT methods applied) + Person Separation Index ≥0.70
? Person Separation Index not determined
− Person Separation Index <0.70
Measurement error + MIC > SDC OR MIC outside the LoA
? MIC not defined
− MIC ≤ SDC OR MIC equals or inside LoA
Reliability + ICC/weighted Kappa ≥0.70, OR Pearson’s r≥ 0.80
? Neither ICC/weighted Kappa, nor Pearson’s r determined
− ICC/weighted Kappa <0.70 OR Pearson’s r < 0.80
Validity
Content validity + All items are considered to be relevant for the construct to be measured, for the
target population, and for the purpose of the measurement AND the questionnaire
is considered to be comprehensive
? Not enough information available
− Not all items are considered to be relevant for the construct to be measured, for the
target population, and for the purpose of the measurement OR the questionnaire is
considered not to be comprehensive
Construct validity
Structural validity (CTT methods applied) + Factors should explain at least 50 % of the variance
? Explained variance not mentioned
− Factors explain <50 % of the variance
Structural validity (IRT methods applied) + Residual correlations among the items after controlling for the dominant factor
<0.20 OR Q3’s <0.37, item scalability >0.30, IRT model fit: G2 >0.01, no DIF for
important subject characteristics (such as age, gender, education): McFadden’s
R2 <0.02, OR no non-uniform DIF
? Important statistics not reported
− Residual correlations among the items after controlling for the dominant factor
≥0.20 OR Q3’s ≥0.37, item scalability ≤0.30, IRT model fit: G2 ≤0.01, important DIF
for important subject characteristics (such as age, gender, education): McFadden’s
R2 ≥0.02, OR non-uniform DIF
Hypothesis testing (convergent/divergent validity) + Correlations with instruments measuring the same construct ≥0.50 OR at least 75 %
of the results are in accordance with the hypotheses AND correlation with related
constructs is higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
− Correlations with instruments measuring the same construct <0.50 OR <75 % of the
results are in accordance with the hypotheses OR correlation with related constructs
is lower than with unrelated constructs
Hypothesis testing (discriminative validity) + Differences in scores on the measurement instrument for all evaluated patient
subgroups are statistically significant OR ≥75 % of results in accordance with
hypotheses
? Some differences statistically significant, others not
− Differences in scores on the measurement instrument for all evaluated patient
subgroups are not statistically significant OR <75 % of results in accordance
with hypotheses
Cross-cultural validity + No differences in factor structure OR no important DIF between language versions
? Multiple group factor analysis not applied AND DIF not assessed
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depending on the results of further validation
studies.
C. QoL measure has low adequacy in at least one
required adequacy criterion (≥1 rating of “minus”)
and therefore is not recommended to be used
anymore.
D. QoL measure has (almost) not been validated. Its
performance in all or most relevant adequacy items
is unclear so that it is not recommended to be used
until further validation studies clarify its adequacy.
Finally, we aim to identify one best (currently available)
instrument to assess QoL in infants, one best (currently
available) instrument to assess QoL in children, and one
best (currently available) instrument to assess QoL in
adolescents with eczema.
Differences between this review and previously
suggested methodology
We refined our eligibility criteria and made clear that
generic QoL instruments will not be eligible for this re-
view [12]. As this review will focus on infants, children,
and adolescents, proxy-reported instruments will also be
included.
Because interpretability and feasibility of a QoL instru-
ment are very important for researchers and clinicians,
we emphasized that corresponding information will be
collected where presented. We also decided to regard
different language versions of the same QoL instrument
separately; this approach was also used in our previous
review on adult QoL instruments [13] but initially not
specified in the pertaining protocol. Content comparison
of the included instruments will be done on content do-
main level instead of item level because a comparison
table on item level would become unclear and confusing
due to the multitude of data shown. Moreover, we de-
cided to use the term “adequacy of the measurement
properties” instead of “quality of the measurement prop-
erties.” For studies applying IRT methods, only internal
consistency, construct validity, structural validity, and
cross-cultural validity will be assessed, where applicable.
Important changes concern the adequacy criteria out-
lined in Table 3:
 For internal consistency, the indeterminate rating
(“?”) was changed from “Dimensionality not known
OR Cronbach’s alpha not determined” to
“Cronbach’s alpha not determined” in order to avoid
an overlap between the adequacy criteria and the
COSMIN criteria for methodological quality.
Adequacy criteria for studies using IRT methods
were added.
 The IRT criteria for structural validity were
enhanced with criteria on differential item
functioning (DIF) [25]. If a study shows that there is
no non-uniform DIF, this can now also result in a
positive rating. Non-uniform DIF will be rated nega-
tively according to the new criteria.
Table 3 Adequacy criteria for measurement properties adapted from [21] and [27] (Continued)
− Differences in factor structure OR important DIF between language versions
Responsiveness
Responsiveness + Correlation with changes on instruments measuring the same construct ≥0.50
OR at least 75 % of the results are in accordance with the hypotheses OR AUC
≥0.70 AND correlations with changes in related constructs are higher than with
unrelated constructs
? Solely correlations determined with unrelated constructs
− Correlations with changes on instruments measuring the same construct <0.50
OR <75 % of the results are in accordance with the hypotheses OR AUC <0.70
OR correlations with changes in related constructs are lower than with unrelated
constructs
MIC minimal important change, SDC smallest detectable change, LoA limits of agreement, ICC intraclass correlation coefficient, AUC area under the curve, +
positive rating, ? indeterminate rating, − negative rating
Table 4 Levels of evidence for the overall adequacy of a measurement property adapted from [28]
Level Rating Criteria
Strong +++, ? (strong) or −−− Consistent findings in multiple studies of good methodological quality OR in one study
of excellent methodological quality
Moderate ++, ? (moderate) or −− Consistent findings in multiple studies of fair methodological quality OR in one study of
good methodological quality
Limited +, ? (limited) or − One study of fair methodological quality
Conflicting +/− Conflicting findings
Unknown ? Only studies of poor methodological quality
+ positive rating, ? indeterminate rating, − negative rating
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 Hypothesis testing was split into its two aspects
convergent/divergent and discriminative validity,
with separate criteria for each aspect, resulting in an
overall rating for hypothesis testing in the end.
 The criteria developed by Terwee et al. for
hypothesis testing will only be applied to convergent
and divergent validity. For discriminative validity,
another aspect of hypothesis testing, self-developed
criteria were added. As the COSMIN initiative does
not consider interpretability to be a formal measure-
ment property, the adequacy criteria for interpret-
ability were omitted [18].
An indeterminate rating for strong, moderate, and lim-
ited levels of evidence was added to the best evidence
synthesis ratings each. This was done for scenarios
where a QoL instrument would obtain an indeterminate
rating for a certain measurement property. An indeter-
minate rating will be assigned to a measurement prop-
erty if there is no clear evidence for either a positive or
negative rating.
Discussion
The proposed systematic review will yield a comprehen-
sive assessment of measurement properties of existing
QoL instruments in infants, children, and adolescents
with eczema. We aim to arrive at a recommendation of
one best instrument for infants, one best instrument for
children, and one best instrument for adolescents, re-
spectively. Rigorous and appropriate methods are vital to
obtain meaningful, scientifically acknowledged results
that form the basis to put forward such recommenda-
tions [6]. With good reason, researchers and clinicians
demand that the development of a COS for eczema
must adhere to high standards. We have made various
efforts to satisfy these expectations. Firstly, the processes
underlying this systematic review are transparent and
systematic. Secondly, the involvement of at least two re-
viewers at each stage will assure quality of and reduce
variability in the assessments. Another strength of the
proposed research is the use of well-established methods
and criteria, such as the COSMIN checklist, that have
been successfully applied in a considerable number of
previous systematic reviews. Furthermore, the inter-
national coverage of the contributing reviewers will
increase the credibility of any findings.
In addition to the results obtained by best evidence
synthesis, the feasibility of a questionnaire, e.g., number
of items and time needed for administration, is another
essential requirement for recommendation. This is also
reflected by the fact that all three criteria of the OMER-
ACT filter, i.e., truth, discrimination, and feasibility, need
to be met by an outcome measure to be recommended
by the HOME initiative [9, 10]. Truth and discrimination
are reflected by the results from best evidence synthesis.
Although there are no adequacy criteria for feasibility,
information on feasibility will be collected throughout
the review process and will be considered for the
conclusions of our systematic review. Sufficient feasi-
bility of a questionnaire is important for its inclusion
in the proposed COS and the widespread implemen-
tation in future eczema trials.
Moreover, we may consider the popularity of a QoL
instrument as an additional parameter for recommenda-
tion if several instruments are placed in category A and
a decision to recommend one of them based solely on
best evidence synthesis is not possible. A potential bene-
fit of well-known and frequently applied QoL instru-
ments could be that more data on the questionnaire’s
feasibility and interpretability of its scores may be avail-
able compared to less popular instruments.
Whether or not we will be able to reach the goal of
recommending one best instrument for each age group
is unclear. It may well be that several instruments will
meet the OMERACT filter criteria. If instruments lack
important requirements, for instance, in relation to re-
sponsiveness or measurement error, they will not comply
with the OMERACT filter criteria, and additional valid-
ation studies will need to be carried out before these
instruments can be included in the COS. As a result, it
could happen that our systematic review will only be
able to identify priorities for further validation work
Table 5 Adequacy criteria required for recommendation of QoL measures for eczema
Adequacy item (name) Inclusion in OMERACT filter Required rating for recommendation
Content validity Truth +
Structural validity Truth +
Hypotheses testing Truth +
Cross-cultural validity Truth +
Internal consistency Discrimination +
Reliability Discrimination +
Measurement error Discrimination +
Responsiveness Discrimination +
Heinl et al. Systematic Reviews  (2016) 5:25 Page 8 of 10
instead of putting forward a clear recommendation for a
certain QoL measurement instrument. Nonetheless, the
findings of this systematic review will inform a
consensus-finding process at the fifth meeting of the
HOME initiative (HOME V) that will take place in São
Paulo, Brazil, in 2017. Based on the findings of this
work, we hope to be able to inform group discussion
and consensus voting with the ultimate goal to endorse
one instrument for each age group to be included in the
core set of outcome measurement instruments for eczema.
Additional files
Additional file 1: PRISMA-P 2015 checklist. The completed PRISMA-P
checklist for this protocol.
Additional file 2: Search strings. The search strings for MEDLINE
(via PubMed) and EMBASE.
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